Patrick M. Reeves
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Patrick M. Reeves has a total of 180 co-authors. Here are the top co-authors by number of shared publications:
- Mark C. Poznansky
Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
10 shared publications Ann E. Sluder
Affiliation Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
5 shared publications- Farah R. W. Kools
Center of Education and Training, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
3 shared publications - Jeffrey A. Gelfand
Wellman Center for Photomedicine, Massachusetts General Hospital (MGH), Boston, MA 02114, USA
3 shared publications Mojgan A. Abbaslou
Vaccine and Immunotherapy Center, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA 02129, USA
3 shared publications- Ruxandra F. Sîrbulescu
Affiliation Vaccine and Immunotherapy Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States of America
3 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF19
New Therapeutic Cancer Vaccine with Lenalidomide Induces Potent T-cell Immunity and Inhibits HPV E6/E7–Expressing Tumor Growth in Mice
Current prophylactic human papillomavirus (HPV) vaccines prevent infection but have limited therapeutic benefit in established HPV-driven malignancies. To address this unmet need, we developed VTX-067, a modular self-assembling therapeutic cancer vaccine consisting of a recombinant Mycobacterium tuberculosis heat shock protein 70–avidin fusion (MAV) noncovalently bound to biotinylated HPV E6/E7 MHC class I– and II–restricted peptide concatemers. MAV is produced in Chinese hamster ovary cells with minimal endotoxin. Assembled VTX-067 is designed to elicit both CD4+ and CD8+ T-cell responses against HPV-associated tumors. In multiple tumor models expressing HPV E6/E7, intradermal vaccination with VTX-067 induced potent and dose-dependent HPV E6/E7–specific CD8+ and CD4+ T-cell responses without evidence of local reactogenicity. Therapeutic vaccination significantly delayed subcutaneous tumor progression, extended survival, and provided durable protection against tumor rechallenge. VTX-067 treatment increased intratumoral CD8+ T-cell infiltration, elevated the CD8:regulatory T-cell ratio, and upregulated a Th1/cytotoxic transcriptional program, including Ifnγ, Tbx21, Stat1, and granzyme B. Depletion of CD8+ T cells eliminated vaccine efficacy, whereas adoptive transfer of VTX-067–primed CD8+ T cells conferred tumor protection in recipient mice. In a cervicovaginal orthotopic model, both intradermal and intramucosal administration generated systemic E6/E7-specific effector responses and sustained control of mucosal tumors. Notably, combining a suboptimal VTX-067 dose with the immunomodulatory agent lenalidomide further enhanced tumor control and survival, demonstrating a potential dose-sparing strategy. These findings establish VTX-067 as a safe, highly immunogenic therapeutic vaccine with CD8+ T cell–dependent antitumor activity and support its clinical development alone or in combination with immune-modulating agents for HPV-associated cancers.
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF19
Open AccessNew Therapeutic Cancer Vaccine with Lenalidomide Induces Potent T-cell Immunity and Inhibits HPV E6/E7–Expressing Tumor Growth in Mice
Current prophylactic human papillomavirus (HPV) vaccines prevent infection but have limited therapeutic benefit in established HPV-driven malignancies. To address this unmet need, we developed VTX-067, a modular self-assembling therapeutic cancer vaccine consisting of a recombinant Mycobacterium tuberculosis heat shock protein 70–avidin fusion (MAV) noncovalently bound to biotinylated HPV E6/E7 MHC class I– and II–restricted peptide concatemers. MAV is produced in Chinese hamster ovary cells with minimal endotoxin. Assembled VTX-067 is designed to elicit both CD4+ and CD8+ T-cell responses against HPV-associated tumors. In multiple tumor models expressing HPV E6/E7, intradermal vaccination with VTX-067 induced potent and dose-dependent HPV E6/E7–specific CD8+ and CD4+ T-cell responses without evidence of local reactogenicity. Therapeutic vaccination significantly delayed subcutaneous tumor progression, extended survival, and provided durable protection against tumor rechallenge. VTX-067 treatment increased intratumoral CD8+ T-cell infiltration, elevated the CD8:regulatory T-cell ratio, and upregulated a Th1/cytotoxic transcriptional program, including Ifnγ, Tbx21, Stat1, and granzyme B. Depletion of CD8+ T cells eliminated vaccine efficacy, whereas adoptive transfer of VTX-067–primed CD8+ T cells conferred tumor protection in recipient mice. In a cervicovaginal orthotopic model, both intradermal and intramucosal administration generated systemic E6/E7-specific effector responses and sustained control of mucosal tumors. Notably, combining a suboptimal VTX-067 dose with the immunomodulatory agent lenalidomide further enhanced tumor control and survival, demonstrating a potential dose-sparing strategy. These findings establish VTX-067 as a safe, highly immunogenic therapeutic vaccine with CD8+ T cell–dependent antitumor activity and support its clinical development alone or in combination with immune-modulating agents for HPV-associated cancers.
- Open Access
- 26 May 2026
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 22 (5) , e1014274
MIAAIM: Multi-omics image integration with dimensional reduction for tissue state mapping
High-parameter tissue imaging enables detailed molecular analysis of single cells within their spatial environment. A current challenge to more complete tissue and single-cell spatial profiling is in situ data alignment across imaging platforms that quantify multiple types of biomolecules at differing resolutions. Here, we describe MIAAIM (Multi-omics Image Alignment and Analysis by Information Manifolds), a modular framework to align and process data from separate imaging technologies with distinct imaging resolutions and data complexity. MIAAIM is designed to be applied to align and analyze images of clinical biopsies from histological staining, imaging mass cytometry, and mass spectrometry imaging. A key advantage of the MIAAIM approach is its capacity to identify unbiased molecular phenotypes that correlate with cell identities and states determined using high-resolution targeted immunodetection. In a large diabetic foot ulcer (DFU) biopsy, this strategy allowed the identification of unique molecular characteristics of infiltrating immune cells as a function of local tissue health. In multi-core tissue microarrays (TMAs) of prostate cancer, MIAAIM allowed the classification of adjacent tumor grades with high accuracy, with over 90% of classification signal sourced from spatial features, generated from segmented cells across multiple imaging modalities while revealing novel cell/ immune signatures of the disease state. MIAAIM provides a disease and cell type agnostic general framework to construct multimodal tissue imaging datasets, yielding novel insights into the association of molecular analytes with cell subsets and their activation states for the analysis of complex tissue states .
- 26 May 2026
- Published by Public Library of Science (PLoS) in PLOS Computational Biology
- Vol. 22 (5) , e1014274
Open AccessMIAAIM: Multi-omics image integration with dimensional reduction for tissue state mapping
High-parameter tissue imaging enables detailed molecular analysis of single cells within their spatial environment. A current challenge to more complete tissue and single-cell spatial profiling is in situ data alignment across imaging platforms that quantify multiple types of biomolecules at differing resolutions. Here, we describe MIAAIM (Multi-omics Image Alignment and Analysis by Information Manifolds), a modular framework to align and process data from separate imaging technologies with distinct imaging resolutions and data complexity. MIAAIM is designed to be applied to align and analyze images of clinical biopsies from histological staining, imaging mass cytometry, and mass spectrometry imaging. A key advantage of the MIAAIM approach is its capacity to identify unbiased molecular phenotypes that correlate with cell identities and states determined using high-resolution targeted immunodetection. In a large diabetic foot ulcer (DFU) biopsy, this strategy allowed the identification of unique molecular characteristics of infiltrating immune cells as a function of local tissue health. In multi-core tissue microarrays (TMAs) of prostate cancer, MIAAIM allowed the classification of adjacent tumor grades with high accuracy, with over 90% of classification signal sourced from spatial features, generated from segmented cells across multiple imaging modalities while revealing novel cell/ immune signatures of the disease state. MIAAIM provides a disease and cell type agnostic general framework to construct multimodal tissue imaging datasets, yielding novel insights into the association of molecular analytes with cell subsets and their activation states for the analysis of complex tissue states .
- Open Access
Immune profiling of responses to influenza vaccination in patients with myeloproliferative neoplasms
Myeloproliferative neoplasms (MPNs) are associated with immune dysregulation and increased susceptibility to infection, emphasizing the importance of vaccination for patients. This pilot study evaluated immune responses to influenza vaccination in MPN patients compared with healthy donors using mass cytometry and serology. We observed diminished CXCR5+ B‐cell, CXCR3+ T‐cell, activated CD127+ memory T‐cell subsets, and a trend toward lower hemagglutinin inhibition titer in MPN patients. These results indicate that patients with MPN exhibit distinct responses to influenza vaccination suggestive of impaired migration to lymphoid organs and T‐cell maturation which may impact the development of protective immunity.
Open AccessImmune profiling of responses to influenza vaccination in patients with myeloproliferative neoplasms
Myeloproliferative neoplasms (MPNs) are associated with immune dysregulation and increased susceptibility to infection, emphasizing the importance of vaccination for patients. This pilot study evaluated immune responses to influenza vaccination in MPN patients compared with healthy donors using mass cytometry and serology. We observed diminished CXCR5+ B‐cell, CXCR3+ T‐cell, activated CD127+ memory T‐cell subsets, and a trend toward lower hemagglutinin inhibition titer in MPN patients. These results indicate that patients with MPN exhibit distinct responses to influenza vaccination suggestive of impaired migration to lymphoid organs and T‐cell maturation which may impact the development of protective immunity.
- 5 April 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (690) , eadd5318
Selective Bcl-2 inhibition promotes hematopoietic chimerism and allograft tolerance without myelosuppression in nonhuman primates
Hematopoietic stem cell transplantation (HSCT) has many potential applications beyond current standard indications, including treatment of autoimmune disease, gene therapy, and transplant tolerance induction. However, severe myelosuppression and other toxicities after myeloablative conditioning regimens have hampered wider clinical use. To achieve donor hematopoietic stem cell (HSC) engraftment, it appears essential to establish niches for the donor HSCs by depleting the host HSCs. To date, this has been achievable only by nonselective treatments such as irradiation or chemotherapeutic drugs. An approach that is capable of more selectively depleting host HSCs is needed to widen the clinical application of HSCT. Here, we show in a clinically relevant nonhuman primate model that selective inhibition of B cell lymphoma 2 (Bcl-2) promoted hematopoietic chimerism and renal allograft tolerance after partial deletion of HSCs and effective peripheral lymphocyte deletion while preserving myeloid cells and regulatory T cells. Although Bcl-2 inhibition alone was insufficient to induce hematopoietic chimerism, the addition of a Bcl-2 inhibitor resulted in promotion of hematopoietic chimerism and renal allograft tolerance despite using only half of the dose of total body irradiation previously required. Selective inhibition of Bcl-2 is therefore a promising approach to induce hematopoietic chimerism without myelosuppression and has the potential to render HSCT more feasible for a variety of clinical indications.
- 5 April 2023
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 15 (690) , eadd5318
Selective Bcl-2 inhibition promotes hematopoietic chimerism and allograft tolerance without myelosuppression in nonhuman primates
Hematopoietic stem cell transplantation (HSCT) has many potential applications beyond current standard indications, including treatment of autoimmune disease, gene therapy, and transplant tolerance induction. However, severe myelosuppression and other toxicities after myeloablative conditioning regimens have hampered wider clinical use. To achieve donor hematopoietic stem cell (HSC) engraftment, it appears essential to establish niches for the donor HSCs by depleting the host HSCs. To date, this has been achievable only by nonselective treatments such as irradiation or chemotherapeutic drugs. An approach that is capable of more selectively depleting host HSCs is needed to widen the clinical application of HSCT. Here, we show in a clinically relevant nonhuman primate model that selective inhibition of B cell lymphoma 2 (Bcl-2) promoted hematopoietic chimerism and renal allograft tolerance after partial deletion of HSCs and effective peripheral lymphocyte deletion while preserving myeloid cells and regulatory T cells. Although Bcl-2 inhibition alone was insufficient to induce hematopoietic chimerism, the addition of a Bcl-2 inhibitor resulted in promotion of hematopoietic chimerism and renal allograft tolerance despite using only half of the dose of total body irradiation previously required. Selective inhibition of Bcl-2 is therefore a promising approach to induce hematopoietic chimerism without myelosuppression and has the potential to render HSCT more feasible for a variety of clinical indications.
- Open Access
- 9 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (49) , eabq6527
Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo
As severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) evolves to escape natural antibodies, it also loses sensitivity to therapeutic antibody drugs. By contrast, evolution selects for binding to ACE2, the cell-surface receptor required for SARS-CoV-2 infection. Consistent with this, we find that an ACE2 decoy neutralizes antibody-resistant variants, including Omicron, with no loss in potency. To identify design features necessary for in vivo activity, we compare several enzymatically inactive, Fc effector–silenced ACE2-Fc decoys. Inclusion of the ACE2 collectrin-like domain not only improves affinity for the S protein but also unexpectedly extends serum half-life and is necessary to reduce disease severity and viral titer in Syrian hamsters. Fc effector function is not required. The activity of ACE2 decoy receptors is due, in part, to their ability to trigger an irreversible structural change in the viral S protein. Our studies provide a new understanding of how ACE2 decoys function and support their development as therapeutics to treat ACE2-dependent coronaviruses.
- 9 December 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (49) , eabq6527
Open AccessOptimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo
As severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) evolves to escape natural antibodies, it also loses sensitivity to therapeutic antibody drugs. By contrast, evolution selects for binding to ACE2, the cell-surface receptor required for SARS-CoV-2 infection. Consistent with this, we find that an ACE2 decoy neutralizes antibody-resistant variants, including Omicron, with no loss in potency. To identify design features necessary for in vivo activity, we compare several enzymatically inactive, Fc effector–silenced ACE2-Fc decoys. Inclusion of the ACE2 collectrin-like domain not only improves affinity for the S protein but also unexpectedly extends serum half-life and is necessary to reduce disease severity and viral titer in Syrian hamsters. Fc effector function is not required. The activity of ACE2 decoy receptors is due, in part, to their ability to trigger an irreversible structural change in the viral S protein. Our studies provide a new understanding of how ACE2 decoys function and support their development as therapeutics to treat ACE2-dependent coronaviruses.
- Open Access
MIAAIM: Multi-omics image integration and tissue state mapping using topological data analysis and cobordism learning
High-parameter tissue imaging enables detailed molecular analysis of single cells in their spatial environment. However, the comprehensive characterization and mapping of tissue states through multimodal imaging across different physiological and pathological conditions requires data integration across multiple imaging systems. Here, we introduce MIAAIM (Multi-omics Image Alignment and Analysis by Information Manifolds) a modular, reproducible computational framework for aligning data across bioimaging technologies, modeling continuities in tissue states, and translating multimodal measures across tissue types. We demonstrate MIAAIM’s workflows across diverse imaging platforms, including histological stains, imaging mass cytometry, and mass spectrometry imaging, to link cellular phenotypic states with molecular microenvironments in clinical biopsies from multiple tissue types with high cellular complexity. MIAAIM provides a robust foundation for the development of computational methods to integrate multimodal, high-parameter tissue imaging data and enable downstream computational and statistical interrogation of tissue states.
Open AccessMIAAIM: Multi-omics image integration and tissue state mapping using topological data analysis and cobordism learning
High-parameter tissue imaging enables detailed molecular analysis of single cells in their spatial environment. However, the comprehensive characterization and mapping of tissue states through multimodal imaging across different physiological and pathological conditions requires data integration across multiple imaging systems. Here, we introduce MIAAIM (Multi-omics Image Alignment and Analysis by Information Manifolds) a modular, reproducible computational framework for aligning data across bioimaging technologies, modeling continuities in tissue states, and translating multimodal measures across tissue types. We demonstrate MIAAIM’s workflows across diverse imaging platforms, including histological stains, imaging mass cytometry, and mass spectrometry imaging, to link cellular phenotypic states with molecular microenvironments in clinical biopsies from multiple tissue types with high cellular complexity. MIAAIM provides a robust foundation for the development of computational methods to integrate multimodal, high-parameter tissue imaging data and enable downstream computational and statistical interrogation of tissue states.
- 15 December 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 201 (12) , 3587-3603
Brief Exposure of Skin to Near-Infrared Laser Modulates Mast Cell Function and Augments the Immune Response
The treatment of skin with a low-power continuous-wave (CW) near-infrared (NIR) laser prior to vaccination is an emerging strategy to augment the immune response to intradermal vaccine, potentially substituting for chemical adjuvant, which has been linked to adverse effects of vaccines. This approach proved to be low cost, simple, small, and readily translatable compared with the previously explored pulsed-wave medical lasers. However, little is known on the mode of laser–tissue interaction eliciting the adjuvant effect. In this study, we sought to identify the pathways leading to the immunological events by examining the alteration of responses resulting from genetic ablation of innate subsets including mast cells and specific dendritic cell populations in an established model of intradermal vaccination and analyzing functional changes of skin microcirculation upon the CW NIR laser treatment in mice. We found that a CW NIR laser transiently stimulates mast cells via generation of reactive oxygen species, establishes an immunostimulatory milieu in the exposed tissue, and provides migration cues for dermal CD103+ dendritic cells without inducing prolonged inflammation, ultimately augmenting the adaptive immune response. These results indicate that use of an NIR laser with distinct wavelength and power is a safe and effective tool to reproducibly modulate innate programs in skin. These mechanistic findings would accelerate the clinical translation of this technology and warrant further explorations into the broader application of NIR lasers to the treatment of immune-related skin diseases.
- 15 December 2018
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 201 (12) , 3587-3603
Brief Exposure of Skin to Near-Infrared Laser Modulates Mast Cell Function and Augments the Immune Response
The treatment of skin with a low-power continuous-wave (CW) near-infrared (NIR) laser prior to vaccination is an emerging strategy to augment the immune response to intradermal vaccine, potentially substituting for chemical adjuvant, which has been linked to adverse effects of vaccines. This approach proved to be low cost, simple, small, and readily translatable compared with the previously explored pulsed-wave medical lasers. However, little is known on the mode of laser–tissue interaction eliciting the adjuvant effect. In this study, we sought to identify the pathways leading to the immunological events by examining the alteration of responses resulting from genetic ablation of innate subsets including mast cells and specific dendritic cell populations in an established model of intradermal vaccination and analyzing functional changes of skin microcirculation upon the CW NIR laser treatment in mice. We found that a CW NIR laser transiently stimulates mast cells via generation of reactive oxygen species, establishes an immunostimulatory milieu in the exposed tissue, and provides migration cues for dermal CD103+ dendritic cells without inducing prolonged inflammation, ultimately augmenting the adaptive immune response. These results indicate that use of an NIR laser with distinct wavelength and power is a safe and effective tool to reproducibly modulate innate programs in skin. These mechanistic findings would accelerate the clinical translation of this technology and warrant further explorations into the broader application of NIR lasers to the treatment of immune-related skin diseases.
- Open Access
- 13 July 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (54) , 30472
Correction: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice
[This corrects the article DOI: 10.18632/oncotarget.21541.].
- 13 July 2018
- Published by Impact Journals, LLC in Oncotarget
- Vol. 9 (54) , 30472
Open AccessCorrection: Ruxolitinib sensitizes ovarian cancer to reduced dose Taxol, limits tumor growth and improves survival in immune competent mice
[This corrects the article DOI: 10.18632/oncotarget.21541.].
- 30 April 2018
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 6 (5) , 539-551
AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral Immunosuppression
AMD3100 (plerixafor), a CXCR4 antagonist, has been demonstrated to suppress tumor growth and modulate intratumoral T-cell trafficking. However, the effect of AMD3100 on immunomodulation remains elusive. Here, we explored immunomodulation and antitumor efficacy of AMD3100 in combination with a previously developed mesothelin-targeted, immune-activating fusion protein, VIC-008, in two syngeneic, orthotopic models of malignant mesothelioma in immunocompetent mice. We showed that combination therapy significantly suppressed tumor growth and prolonged animal survival in two mouse models. Tumor control and survival benefit were associated with enhanced antitumor immunity. VIC-008 augmented mesothelin-specific CD8+ T-cell responses in the spleen and lymph nodes and facilitated intratumoral lymphocytic infiltration. However, VIC-008 treatment was associated with increased programmed cell death protein-1 (PD-1) expression on intratumoral CD8+ T cells, likely due to high CXCL12 in the tumor microenvironment. AMD3100 alone and in combination with VIC-008 modulated immunosuppression in tumors and the immune system through suppression of PD-1 expression on CD8+ T cells and conversion of regulatory T cells (Tregs) into CD4+CD25–Foxp3+IL2+CD40L+ helper-like cells. In mechanistic studies, we demonstrated that AMD3100-driven Treg reprogramming required T cell receptor (TCR) activation and was associated with loss of PTEN due to oxidative inactivation. The combination of VIC-008 augmentation of tumor-specific CD8+ T-cell responses with AMD3100 abrogation of immunosuppression conferred significant benefits for tumor control and animal survival. These data provide new mechanistic insight into AMD3100-mediated immunomodulation and highlight the enhanced antitumor effect of AMD3100 in combination with a tumor antigen–targeted therapy in mouse malignant mesothelioma, which could be clinically relevant to patients with this difficult-to-treat disease. Cancer Immunol Res; 6(5); 539–51. ©2018 AACR.
- 30 April 2018
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 6 (5) , 539-551
AMD3100 Augments the Efficacy of Mesothelin-Targeted, Immune-Activating VIC-008 in Mesothelioma by Modulating Intratumoral Immunosuppression
AMD3100 (plerixafor), a CXCR4 antagonist, has been demonstrated to suppress tumor growth and modulate intratumoral T-cell trafficking. However, the effect of AMD3100 on immunomodulation remains elusive. Here, we explored immunomodulation and antitumor efficacy of AMD3100 in combination with a previously developed mesothelin-targeted, immune-activating fusion protein, VIC-008, in two syngeneic, orthotopic models of malignant mesothelioma in immunocompetent mice. We showed that combination therapy significantly suppressed tumor growth and prolonged animal survival in two mouse models. Tumor control and survival benefit were associated with enhanced antitumor immunity. VIC-008 augmented mesothelin-specific CD8+ T-cell responses in the spleen and lymph nodes and facilitated intratumoral lymphocytic infiltration. However, VIC-008 treatment was associated with increased programmed cell death protein-1 (PD-1) expression on intratumoral CD8+ T cells, likely due to high CXCL12 in the tumor microenvironment. AMD3100 alone and in combination with VIC-008 modulated immunosuppression in tumors and the immune system through suppression of PD-1 expression on CD8+ T cells and conversion of regulatory T cells (Tregs) into CD4+CD25–Foxp3+IL2+CD40L+ helper-like cells. In mechanistic studies, we demonstrated that AMD3100-driven Treg reprogramming required T cell receptor (TCR) activation and was associated with loss of PTEN due to oxidative inactivation. The combination of VIC-008 augmentation of tumor-specific CD8+ T-cell responses with AMD3100 abrogation of immunosuppression conferred significant benefits for tumor control and animal survival. These data provide new mechanistic insight into AMD3100-mediated immunomodulation and highlight the enhanced antitumor effect of AMD3100 in combination with a tumor antigen–targeted therapy in mouse malignant mesothelioma, which could be clinically relevant to patients with this difficult-to-treat disease. Cancer Immunol Res; 6(5); 539–51. ©2018 AACR.
- 1 November 2017
- Published by Wiley in The FASEB Journal
- Vol. 32 (1) , 5-15
Application and utility of mass cytometry in vaccine development
Mass cytometry enables highly multiplexed profiling of cellular immune responses in limited‐volume samples, advancing prospects of a new era of systems immunology. The capabilities of mass cytometry offer expanded potential for deciphering immune responses to infectious diseases and to vaccines. Several studies have used mass cytometry to profile protective immune responses, both postinfection and postvaccination, although no vaccine‐development program has yet systematically employed the technology from the outset to inform both candidate design and clinical evaluation. In this article, we review published mass cytometry studies relevant to vaccine development, briefly compare immune profiling by mass cytometry to other systems‐level technologies, and discuss some general considerations for deploying mass cytometry in the context of vaccine development.— Reeves, P. M., Sluder, A. E., Raju Paul, S., Scholzen, A., Kashiwagi, S., Poznansky, M. C. Application and utility of mass cytometry in vaccine development. FASEB J. 32,5‐15 (2018). www.fasebj.org
- 1 November 2017
- Published by Wiley in The FASEB Journal
- Vol. 32 (1) , 5-15
Application and utility of mass cytometry in vaccine development
Mass cytometry enables highly multiplexed profiling of cellular immune responses in limited‐volume samples, advancing prospects of a new era of systems immunology. The capabilities of mass cytometry offer expanded potential for deciphering immune responses to infectious diseases and to vaccines. Several studies have used mass cytometry to profile protective immune responses, both postinfection and postvaccination, although no vaccine‐development program has yet systematically employed the technology from the outset to inform both candidate design and clinical evaluation. In this article, we review published mass cytometry studies relevant to vaccine development, briefly compare immune profiling by mass cytometry to other systems‐level technologies, and discuss some general considerations for deploying mass cytometry in the context of vaccine development.— Reeves, P. M., Sluder, A. E., Raju Paul, S., Scholzen, A., Kashiwagi, S., Poznansky, M. C. Application and utility of mass cytometry in vaccine development. FASEB J. 32,5‐15 (2018). www.fasebj.org